In papers presented at the International Neuromodulation Society’s 12th World Congress in Montreal earlier this summer, urologists from Beaumont Hospital, Royal Oak, Michigan, presented conclusions from their studies of neuromodulation demonstrating its effectiveness as a therapy for treating bladder and pelvic pain. Estimates are that some 30 million Americans suffer from the former condition and up to 1 in 7 women are affected by chronic pelvic pain. Both have substantial bearing on the patient’s quality of life as well as overall health. The team’s research, consisting of 3 separate investigations, was funded by the Ministrelli Program for Urology Research and Education, or MPURE.
Neuromodulation involves providing electrical stimulation to different nerves—pudendal, sacral, and tibial. The pudendal nerve controls the pelvic region, including the bladder and bowels. Electrical stimulation to the sacral nerves is thought to normalize communication between the bladder and bowel and the brain, enabling improved functioned. In summary, the team reported that of patients with bladder pain who failed to respond to sacral neuromodulation, more than 90% benefitted from pudendal neuromodulation as an alternative. In answer to the conventional belief that high body mass index negatively impacts neuromodulation outcomes, the team reported their findings that, while patients with a BMI greater than 30 did have greater reoperation rates, the fact did not change overall outcomes or complications. Addressing the common assumption that smaller bladder capacity is linked to reduced benefit from neuromodulation, the Beaumont team again found this not to be the case.
Read a news story about the research findings here.
Read about the first wireless neuromodulation device for relief of chronic back and leg pain, here.
Learn more about neuromodulation, and how is it affected by music, by viewing these slides.
Posted on August 19, 2015